In line with the data in previous studies,37,45 omalizumab decreased surface FcεRI levels on blood mDCs of asthma patients (Fig 2, B, left), although omalizumab could decrease FcεRI expression levels on mDCs of both those with and without response (Fig 2, B, right). Here, FCER1A is linked to asthma.